Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Launches US-based Subsidiary to Drive Protein-Protein Interaction Business

Premium

French biotech firm Hybrigenics said this week that it has incorporated a US-based subsidiary, Hybrigenics Corporation.

To be based in Cambridge, Mass., the subsidiary will focus primarily on Hybrigenics' protein-protein interaction fee-for-service business, and will represent the company for US-based "R&D, regulatory, and business development matters," it said.

Hybrigenics' protein-protein interaction business currently generates more than 30 percent of its total revenues in the US, or roughly €1 million ($1.35 million) per year, the company said.

It added that, with launch of the subsidiary, it aims to "significantly boost American revenues."

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.